RemeGen Fast-Tracks Potential World-First BLys/APRIL Agent For gMG In Global Phase III Trial

RemeGen is planning to complete enrolment in the global Phase III RemeMG study with telitacicept in generalized myasthenia gravis by the end of 2025 or early 2026. The Chinese firm has already sidelined two other global Phase III trials with the molecule to prioritize the indication.

PatientRecruitment
RemeGen is pulling out all the stops to enroll patients in a global Phase III clincial trial in generalized myasthenia gravis. • Source: Shutterstock

Despite struggling with the financial burden, Chinese firm RemeGen is pulling out all the stops for its ongoing global Phase III RemeMG study to repeat the positive safety and efficacy outcomes from a similar China-only study with telitacicept, its backbone asset for autoimmune disorders, in generalized myasthenia gravis (gMG).

Key Takeaways
  • Chinese firm RemeGen is aiming to complete recruitment in a global Phase III trial with telitacicept in generalized myasthenia gravis by the end of 2025 or early 2026.

If RemeMG turns out to meet its endpoints, telitacicept is set to become the first successful fusion protein worldwide that...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Dynavax Aims To Disrupt GSK’s Shingrix Market With More Tolerable Shingles Vaccine

 
• By 

Phase I/II head-to-head data show Dynavax’s Z-1018 had similar immunogenicity and much improved tolerability versus Shingrix, prompting a move into Part 2 of the study.

Nicox Plots US Submission After Another Phase III Glaucoma Win

 
• By 

The France-headquartered firm’s eye drop has demonstrated efficacy in a second pivotal trial.

Rocket’s Warp Drive Back Online As FDA Lifts Danon Gene Therapy Hold

 

The company took a prophylactic C3 inhibitor out of the immunomodulatory regimen used in its Phase II study of RP-A501, lowered the dose and adjusted its use of eculizumab.

Celldex Bullish On Barzolvolimab Despite Study Miss

 
• By 

All eyes on chronic urticaria after eosinophilic esophagitis disappointment.

More from Rare Diseases

Another Day Another Win For Novartis’s Ianalumab – This Time In ITP

 
• By 

The Swiss drugmaker’s BAFF-R inhibitor and ADCC-mediated B-cell depletor candidate has chalked up another win in late-stage development, further strengthening its pipeline-in-a-product bid.

Prasad’s Exit From CBER Could Bode Well For Genetic Medicines

 

Pharma companies like Sarepta, Replimune and Capricor made gains on Wall Street after news broke that the FDA Center for Biologics Evaluation and Research director Vinay Prasad is leaving.

PTC To Challenge BioMarin In PKU With Oral Sephience

 
• By 

PTC plans to compete with BioMarin’s two phenylketonuria drugs with efficacy data showing strong reduction of phenylalanine and ability for patients to liberalize their diets.